VERTEX PHARMACEUTICALS INC (VX1.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:VX1 - US92532F1003 - Common Stock
394.9 EUR
+5.05 (+1.3%)
We assign a fundamental rating of 7 out of 10 to VX1. VX1 was compared to 81 industry peers in the Biotechnology industry. VX1 has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. VX1 has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! This makes VX1 very considerable for value and growth and quality investing!
1. Profitability
1.1 Basic Checks
In the past year VX1 was profitable.
VX1 had a positive operating cash flow in the past year.
Of the past 5 years VX1 4 years were profitable.
VX1 had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
VX1 has a Return On Assets of 14.78%. This is amongst the best in the industry. VX1 outperforms 88.89% of its industry peers.
VX1 has a better Return On Equity (21.22%) than 92.59% of its industry peers.
VX1's Return On Invested Capital of 15.66% is amongst the best of the industry. VX1 outperforms 93.83% of its industry peers.
VX1 had an Average Return On Invested Capital over the past 3 years of 17.53%. This is significantly above the industry average of 11.80%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.78% | ||
| ROE | 21.22% | ||
| ROIC | 15.67% |
ROA(3y)10.62%
ROA(5y)14.47%
ROE(3y)13.73%
ROE(5y)19.12%
ROIC(3y)17.53%
ROIC(5y)18.06%
1.3 Margins
VX1 has a Profit Margin of 31.35%. This is amongst the best in the industry. VX1 outperforms 86.42% of its industry peers.
With an excellent Operating Margin value of 38.70%, VX1 belongs to the best of the industry, outperforming 93.83% of the companies in the same industry.
VX1's Operating Margin has improved in the last couple of years.
The Gross Margin of VX1 (86.28%) is better than 79.01% of its industry peers.
VX1's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 38.7% | ||
| PM (TTM) | 31.35% | ||
| GM | 86.28% |
OM growth 3Y2.79%
OM growth 5Y6.75%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y-0.17%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so VX1 is creating value.
The number of shares outstanding for VX1 has been reduced compared to 1 year ago.
Compared to 5 years ago, VX1 has less shares outstanding
VX1 has a better debt/assets ratio than last year.
2.2 Solvency
VX1 has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | N/A |
ROIC/WACC1.78
WACC8.78%
2.3 Liquidity
VX1 has a Current Ratio of 2.36. This indicates that VX1 is financially healthy and has no problem in meeting its short term obligations.
VX1 has a Current ratio (2.36) which is comparable to the rest of the industry.
A Quick Ratio of 2.00 indicates that VX1 should not have too much problems paying its short term obligations.
VX1 has a Quick ratio of 2.00. This is comparable to the rest of the industry: VX1 outperforms 46.91% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.36 | ||
| Quick Ratio | 2 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 3303.92% over the past year.
The earnings per share for VX1 have been decreasing by -44.14% on average. This is quite bad
VX1 shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.33%.
The Revenue has been growing by 21.50% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)3303.92%
EPS 3Y-71.86%
EPS 5Y-44.14%
EPS Q2Q%9.59%
Revenue 1Y (TTM)10.33%
Revenue growth 3Y13.31%
Revenue growth 5Y21.5%
Sales Q2Q%10.99%
3.2 Future
Based on estimates for the next years, VX1 will show a very strong growth in Earnings Per Share. The EPS will grow by 150.35% on average per year.
Based on estimates for the next years, VX1 will show a quite strong growth in Revenue. The Revenue will grow by 9.70% on average per year.
EPS Next Y6343.89%
EPS Next 2Y739.72%
EPS Next 3Y328.89%
EPS Next 5Y150.35%
Revenue Next Year10.14%
Revenue Next 2Y9.44%
Revenue Next 3Y9.38%
Revenue Next 5Y9.7%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 26.74, which means the current valuation is very expensive for VX1.
Based on the Price/Earnings ratio, VX1 is valued a bit cheaper than the industry average as 79.01% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of VX1 to the average of the S&P500 Index (26.51), we can say VX1 is valued inline with the index average.
With a Price/Forward Earnings ratio of 22.69, VX1 is valued on the expensive side.
VX1's Price/Forward Earnings ratio is rather cheap when compared to the industry. VX1 is cheaper than 82.72% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of VX1 to the average of the S&P500 Index (23.13), we can say VX1 is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.74 | ||
| Fwd PE | 22.69 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, VX1 is valued a bit cheaper than the industry average as 74.07% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, VX1 is valued cheaply inside the industry as 81.48% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 35.28 | ||
| EV/EBITDA | 23.53 |
4.3 Compensation for Growth
VX1's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of VX1 may justify a higher PE ratio.
VX1's earnings are expected to grow with 328.89% in the coming years. This may justify a more expensive valuation.
PEG (NY)0
PEG (5Y)N/A
EPS Next 2Y739.72%
EPS Next 3Y328.89%
5. Dividend
5.1 Amount
VX1 does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
FRA:VX1 (12/30/2025, 1:58:00 PM)
394.9
+5.05 (+1.3%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners97.5%
Inst Owner ChangeN/A
Ins Owners0.13%
Ins Owner ChangeN/A
Market Cap100.19B
Revenue(TTM)11.72B
Net Income(TTM)3.68B
Analysts76.41
Price Target425.31 (7.7%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.29%
Min EPS beat(2)3.12%
Max EPS beat(2)3.45%
EPS beat(4)2
Avg EPS beat(4)-0.92%
Min EPS beat(4)-7.2%
Max EPS beat(4)3.45%
EPS beat(8)5
Avg EPS beat(8)-64.05%
EPS beat(12)7
Avg EPS beat(12)-42.39%
EPS beat(16)10
Avg EPS beat(16)-31.28%
Revenue beat(2)1
Avg Revenue beat(2)-0.58%
Min Revenue beat(2)-1.21%
Max Revenue beat(2)0.06%
Revenue beat(4)2
Avg Revenue beat(4)-0.82%
Min Revenue beat(4)-4.8%
Max Revenue beat(4)2.68%
Revenue beat(8)3
Avg Revenue beat(8)-0.69%
Revenue beat(12)4
Avg Revenue beat(12)-0.78%
Revenue beat(16)7
Avg Revenue beat(16)-0.32%
PT rev (1m)-1.28%
PT rev (3m)2.14%
EPS NQ rev (1m)0.05%
EPS NQ rev (3m)2.35%
EPS NY rev (1m)1.67%
EPS NY rev (3m)1.53%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.83%
Revenue NY rev (1m)0.05%
Revenue NY rev (3m)0.1%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.74 | ||
| Fwd PE | 22.69 | ||
| P/S | 10.04 | ||
| P/FCF | 35.28 | ||
| P/OCF | 31.66 | ||
| P/B | 6.8 | ||
| P/tB | 7.45 | ||
| EV/EBITDA | 23.53 |
EPS(TTM)14.77
EY3.74%
EPS(NY)17.4
Fwd EY4.41%
FCF(TTM)11.19
FCFY2.83%
OCF(TTM)12.47
OCFY3.16%
SpS39.32
BVpS58.09
TBVpS53
PEG (NY)0
PEG (5Y)N/A
Graham Number138.95
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.78% | ||
| ROE | 21.22% | ||
| ROCE | 22.25% | ||
| ROIC | 15.67% | ||
| ROICexc | 22.65% | ||
| ROICexgc | 25.38% | ||
| OM | 38.7% | ||
| PM (TTM) | 31.35% | ||
| GM | 86.28% | ||
| FCFM | 28.47% |
ROA(3y)10.62%
ROA(5y)14.47%
ROE(3y)13.73%
ROE(5y)19.12%
ROIC(3y)17.53%
ROIC(5y)18.06%
ROICexc(3y)43.35%
ROICexc(5y)48.92%
ROICexgc(3y)62.02%
ROICexgc(5y)75.97%
ROCE(3y)24.89%
ROCE(5y)25.65%
ROICexgc growth 3Y-29.98%
ROICexgc growth 5Y-9.76%
ROICexc growth 3Y-22.64%
ROICexc growth 5Y-1.94%
OM growth 3Y2.79%
OM growth 5Y6.75%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y-0.17%
F-Score7
Asset Turnover0.47
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 189.83% | ||
| Cap/Sales | 3.25% | ||
| Interest Coverage | 374.91 | ||
| Cash Conversion | 78.49% | ||
| Profit Quality | 90.81% | ||
| Current Ratio | 2.36 | ||
| Quick Ratio | 2 | ||
| Altman-Z | N/A |
F-Score7
WACC8.78%
ROIC/WACC1.78
Cap/Depr(3y)171.61%
Cap/Depr(5y)187.83%
Cap/Sales(3y)3.11%
Cap/Sales(5y)3.32%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)3303.92%
EPS 3Y-71.86%
EPS 5Y-44.14%
EPS Q2Q%9.59%
EPS Next Y6343.89%
EPS Next 2Y739.72%
EPS Next 3Y328.89%
EPS Next 5Y150.35%
Revenue 1Y (TTM)10.33%
Revenue growth 3Y13.31%
Revenue growth 5Y21.5%
Sales Q2Q%10.99%
Revenue Next Year10.14%
Revenue Next 2Y9.44%
Revenue Next 3Y9.38%
Revenue Next 5Y9.7%
EBIT growth 1Y5.79%
EBIT growth 3Y16.47%
EBIT growth 5Y29.7%
EBIT Next Year811.13%
EBIT Next 3Y128.24%
EBIT Next 5Y68.84%
FCF growth 1Y-20.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-15.14%
OCF growth 3YN/A
OCF growth 5YN/A
VERTEX PHARMACEUTICALS INC / VX1.DE FAQ
What is the ChartMill fundamental rating of VERTEX PHARMACEUTICALS INC (VX1.DE) stock?
ChartMill assigns a fundamental rating of 7 / 10 to VX1.DE.
What is the valuation status for VX1 stock?
ChartMill assigns a valuation rating of 7 / 10 to VERTEX PHARMACEUTICALS INC (VX1.DE). This can be considered as Undervalued.
What is the profitability of VX1 stock?
VERTEX PHARMACEUTICALS INC (VX1.DE) has a profitability rating of 8 / 10.
How financially healthy is VERTEX PHARMACEUTICALS INC?
The financial health rating of VERTEX PHARMACEUTICALS INC (VX1.DE) is 7 / 10.
What is the earnings growth outlook for VERTEX PHARMACEUTICALS INC?
The Earnings per Share (EPS) of VERTEX PHARMACEUTICALS INC (VX1.DE) is expected to grow by 6343.89% in the next year.